Efficacy and safety of GLP-1 agonists in the treatment of T2DM: A systematic review and network meta-analysis

Efficacy and safety of GLP-1 agonists in the treatment of T2DM: A systematic review and network meta-analysis

Abstract To compare efficacy and safety of glucagon-like peptide-1 receptor agonists (GLP-1RAs) in subjects with type 2 diabetes (T2DM). Electronic databases were searched from inception to 2nd October 2024 for randomised controlled trials comparing GLP-1RAs treating T2DM. Bayesian network meta-anal...

Full description

Saved in:

Bibliographic Details
Main Authors:	Xiaoyu Ren, Honghao Hua, Yuanqin Wu, Wei Zhang, Xianzhen Long, Yana Bai, Ning Cheng
Format:	Article
Language:	English
Published:	Nature Portfolio 2025-07-01
Series:	Scientific Reports
Subjects:	Network meta-analysis Glucagon-like peptide-1 receptor agonists Type 2 diabetes mellitus
Online Access:	https://doi.org/10.1038/s41598-025-09807-0
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

GLP-1 and Its Role in Glycogen Production: A Narrative Review
by: Joseph Lotosky, et al.
Published: (2025-06-01)

Decreased incidence of hidradenitis suppurativa and psoriasis in diabetic patients treated with GLP-1 receptor agonists: A retrospective cohort study
by: Lauren M. Ching, BS, et al.
Published: (2025-10-01)

Dionysus or apollo, skeletal muscle mass changes in type 2 diabetes with sarcopenia receiving GLP-1 receptor agonist: systematic review and meta-analysis
by: Yanying Wang, et al.
Published: (2025-08-01)

Nutritional priorities to support GLP-1 therapy for obesity: A joint advisory from the American College of Lifestyle Medicine, the American Society for Nutrition, the Obesity Medicine Association, and the Obesity Society
by: Dariush Mozaffarian, et al.
Published: (2025-09-01)

GLP-1 receptor agonists in Parkinson’s disease: an updated comprehensive systematic review with meta-analysis
by: Mohamed Mohsen Helal, et al.
Published: (2025-08-01)

Efficacy and safety of glucagon-like peptide-1 receptor agonists therapy initiation in patients with type 2 diabetes hospitalized with coronavirus infection
by: T. N. Markova, et al.
Published: (2023-12-01)

Glucagon-Like Peptide-1 and Hypothalamic Regulation of Satiation: Cognitive and Neural Insights from Human and Animal Studies
by: Joon Seok Park, et al.
Published: (2025-05-01)

A comparison of Glucagon-like peptide-1 receptor agonists on weight change, side effects, and quality of life in Kuwait
by: Saleh Alali, et al.
Published: (2025-05-01)

Association of Glucagon‐Like Peptide Agonist Therapy With Dietary Patterns in a Cross‐Sectional Cohort
by: Eric J. Brandt, et al.
Published: (2025-06-01)

Glucagon-like peptide-1 receptor agonist-induced cholecystitis and cholelithiasis: a real-world pharmacovigilance analysis using the FAERS database
by: Chao Tao, et al.
Published: (2025-07-01)

Efficacy and Safety of Glucagon‐Like Peptide‐1 Agonists for Psychiatric Symptoms: A Systematic Review
by: Shakila Meshkat, et al.
Published: (2025-07-01)

Glucagon-like peptide 1 receptor agonists and cancer risk: advancing precision medicine through mechanistic understanding and clinical evidence
by: Anqi Lin, et al.
Published: (2025-03-01)

Promising areas of pharmacotherapy for obesity
by: M. A. Druzhilov, et al.
Published: (2021-04-01)

Impact of changes in conventional risk factors induced by once-weekly GLP-1 receptor agonist exenatide on cardiovascular outcomes: an EXSCEL post hoc analysis
by: Ruth L. Coleman, et al.
Published: (2025-08-01)

Investigation of potential relationship between glucagon-like peptide 1 receptor agonists with suicide/self-injury: disproportionality analysis using WHO-VigiBase
by: Ye Young Kim, et al.
Published: (2024-12-01)

Characteristics of patients prescribed SGLT-2i and/or GLP-1RA among cardiology clinics in the US: insights from the COORDINATE-diabetes trial
by: Adam J Nelson, et al.
Published: (2025-09-01)

Physiology and pharmacology of glucagon-like peptide-1 receptor
by: D. V. Kurkin, et al.
Published: (2024-01-01)

Endocrine and metabolic effects of GLP-1 receptor agonists on women with PCOS, a narrative review
by: Marine Monney, et al.
Published: (2025-03-01)

Exploring the multifaceted roles of GLP-1 receptor agonists; a comprehensive review
by: Bisma Fatima Hammad, et al.
Published: (2025-07-01)

Perioperative Practice Patterns of Anaesthesiologists Surrounding Glucagon-Like Peptide-1 (GLP-1) Agonist Medications
by: Meghan Brennan, et al.
Published: (2025-04-01)

A Case Series on the Efficacy of the Pharmacological Treatment of Lipedema: The Italian Experience with Exenatide
by: Laura Patton, et al.
Published: (2025-07-01)

GLP-1 agonists in anaesthetic practice - a review of clinical data and recommendations
by: Natalia Pokrywka, et al.
Published: (2025-07-01)

Efficacy of liraglutide in patients with metabolic-associated steatotic liver disease in type 2 diabetes mellitus
by: Yu.M. Stepanov, et al.
Published: (2025-06-01)

Pharmalogical effects and results of clinical trials of the first incretinomimetic exenatide
by: Alexander Sergeevich Ametov, et al.
Published: (2011-09-01)

Once-weekly administration of dulaglutide, a glucagon-like peptide-1 receptor agonist, as monotherapy and combination therapy: review of the AWARD studies
by: Marina V. Shestakova, et al.
Published: (2017-08-01)

Higher Compliance with Treatment Administration Instructions for Injectable Dulaglutide versus Oral Semaglutide Reported by People with Type 2 Diabetes in Clinical Practice Settings in Spain: The TRU-Experience Study
by: Díaz-Cerezo S, et al.
Published: (2025-05-01)

Prior metabolic surgery attenuates the weight-loss efficacy of liraglutide in patients with mild obesity
by: Yuqin Ouyang, et al.
Published: (2025-05-01)

Association between GLP-1 receptor agonists as a class and colorectal cancer risk: a meta-analysis of retrospective cohort studies
by: Ying Zhong, et al.
Published: (2025-08-01)

Exploring the Role of GLP-1 Receptor Agonists in Alzheimer’s Disease: A Review of Preclinical and Clinical Evidence
by: Lívia C. R. Teixeira, et al.
Published: (2025-01-01)

Glucagon-like Peptide-1 Receptor Agonists (GLP-1 RAs): A Pan-Steatotic Liver Disease Treatment?
by: Lampros Chrysavgis, et al.
Published: (2025-06-01)

Emerging concepts in obesity management: focus on glucagon receptor agonist combinations
by: Sarah L Anderson
Published: (2025-07-01)

Research progress on the effect of type 2 diabetes and hypoglycemic drugs on the prognosis of patients with colorectal cancer
by: ZHANG Meng，LEI Xuefen，CHEN Haixia，CHEN Yixuan，JIANG Li
Published: (2025-07-01)

Addressing weight loss management in obese gout patients: guidance for future trials
by: Robin Christensen, et al.
Published: (2024-11-01)

Downstream interaction by glucagon-like peptide-1 and glucose-dependent insulinotropic polypeptide agonism is required for synergistic effects on body weight
by: Claire H. Feetham, et al.
Published: (2025-09-01)

Glucagon and Glucose Availability Influence Metabolic Heterogeneity and Malignancy in Pancreatic Neuroendocrine Tumour (pNET) Cells: Novel Routes for Therapeutic Targeting
by: Bárbara Ferreira, et al.
Published: (2025-06-01)

Objective Evaluation of Relationship Between Tear Film Stability and Visual Fatigue [Letter]
by: Bandyopadhyay A, et al.
Published: (2025-08-01)

Russian development for drug independence in endocrinology: comparative analysis of bioequivalence, safety and tolerability of the first domestic liraglutide
by: A. S. Ametov, et al.
Published: (2023-11-01)

GLP-1 receptor agonists in IBD: exploring the crossroads of metabolism and inflammation
by: Giulia Migliorisi, et al.
Published: (2025-07-01)

REBOUND OBESITY AFTER GLP-1 AGONISTS DISCONTINUATION
by: Zainab M. Al-Shammaa, et al.
Published: (2025-07-01)

Efficacy and safety of GLP-1 receptor agonists on weight management and metabolic parameters in PCOS women: a meta-analysis of randomized controlled trials
by: Shike Lin, et al.
Published: (2025-05-01)